Investigational New Drugs

, Volume 29, Issue 1, pp 192–194 | Cite as

TNF-blockade in patients with advanced hormone refractory prostate cancer

  • Luis A. DiazJr
  • Wells Messersmith
  • Lori Sokoll
  • Vicki Sinibaldi
  • Sandy Moore
  • Michael Carducci
  • Mario Eisenberger
SHORT REPORT

Keywords

Prostate cancer Hormone refractory TNF-alpha Infliximab IL-6 

Supplementary material

10637_2009_9346_MOESM1_ESM.pdf (31 kb)
ESM 1(PDF 30 kb)

References

  1. 1.
    Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY et al (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542–549CrossRefPubMedGoogle Scholar
  2. 2.
    Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM et al (2001) Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58:1008–1015CrossRefPubMedGoogle Scholar
  3. 3.
    George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ et al (2005) The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 11:1815–1820CrossRefPubMedGoogle Scholar
  4. 4.
    Woods Ignatoski KM, Friedman J, Escara-Wilke J, Zhang X, Daignault S, et al. (2009) Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy. J Interferon Cytokine Res 29(2):105–112. doi:10.1089/jir.2008.0024 CrossRefGoogle Scholar
  5. 5.
    Malinowska K, Neuwirt H, Cavarretta I, Bektic J, Steiner H, et al. (2008) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16(1):155–169. doi:10.1677/ERC-08-0174 CrossRefPubMedGoogle Scholar
  6. 6.
    Wegiel B, Bjartell A, Culig Z, Persson JL (2008) Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 122:1521–1529CrossRefPubMedGoogle Scholar
  7. 7.
    Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F et al (2007) The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol 25:477–489CrossRefPubMedGoogle Scholar
  8. 8.
    Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH et al (2007) The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26:2822–2832CrossRefPubMedGoogle Scholar
  9. 9.
    Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J et al (2006) Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate 66:1744–1752CrossRefPubMedGoogle Scholar
  10. 10.
    Smith PC, Keller ET (2001) Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48:47–53CrossRefPubMedGoogle Scholar
  11. 11.
    Okamoto M, Lee C, Oyasu R (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141–146PubMedGoogle Scholar
  12. 12.
    Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction–a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448–457CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Luis A. DiazJr
    • 1
    • 2
  • Wells Messersmith
    • 3
  • Lori Sokoll
    • 2
    • 4
  • Vicki Sinibaldi
    • 2
  • Sandy Moore
    • 2
  • Michael Carducci
    • 2
  • Mario Eisenberger
    • 2
  1. 1.The Ludwig Center for Cancer Genetics & Therapeutics at Johns HopkinsBaltimoreUSA
  2. 2.Department of OncologyJohns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimoreUSA
  3. 3.Division of Medical OncologyUniversity of Colorado Cancer CenterAuroraUSA
  4. 4.Department of PathologyJohns Hopkins Medical InstitutesBaltimoreUSA

Personalised recommendations